Evaluation of screening tests to prevent transfusion-associated non-A non-B hepatitis
Fleurette F, Durieux P
Record ID 31995000088
To determine the optimal prevention strategy for transfusion associated non-A non-B hepatitis at the request of the French Department of Health. The expert panel defined the following issues: frequency of transfusion-associated non-A non-B hepatitis, clinical course of the disease, efficacy of surrogate and direct tests.
Authors' results and conclusions:
Non-A non-B hepatitis constitutes the major transfusion-associated infection risk.50% of cases become chronic, 20% progress to cirrhosis. Surrogate tests (ALT and anti-HBc) and a direct test (anti-HCV) can be used. Only anti-HCV can decrease the incidence of transfusion-associated non-A non-B hepatitis by more than 50%. More than 80% of anti-HCV+blood samples are not detected by surrogate tests.
Anti-HCV testing is clearly the most effective strategy, but various policies can be adopted given the uncertainties of scientific and cost data. We recommended that surrogate tests be used in addition to the anti-HCV test in all French blood banks.
Other output or dissemination activity: This is the current French policy.
English language abstract:
An English language summary is available
- Blood Banks
- Blood Transfusion
- Mass Screening
L'Agence Nationale d'Accreditation d'Evaluation en Santé
2 avenue du Stade de France, 93218 Saint-Denis La Plaine Cedex, France. Tel: +33 01 55 93 71 88; Fax: +33 01 55 93 74 35;
Agence Nationale pour le Developpement de l'Evaluation Medicale